TY - JOUR
T1 - Using rercentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma
AU - Kim, Timothy
AU - Zargar-Shoshtari, Kamran
AU - Dhillon, Jasreman
AU - Lin, Hui Yi
AU - Yue, Binglin
AU - Fishman, Mayer
AU - Sverrisson, Einar F.
AU - Spiess, Philippe E.
AU - Gupta, Shilpa
AU - Poch, Michael A.
AU - Sexton, Wade J.
N1 - Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Abstract Background The objective of this study was to determine if the percentage of sarcomatoid differentiation (%Sarc) in renal cell carcinoma (RCC) can be used for prognostic risk stratification, because sarcomatoid RCC (sRCC) is an aggressive variant of kidney cancer. Patients and Methods We performed a retrospective analysis of patients who underwent surgery for RCC at our institution between 1999 and 2012. Pathology slides for all sRCC cases were reexamined by a single pathologist and %Sarc was calculated. %Sarc was analyzed as a continuous variable and as a categorical variable at cut points of 5%, 10%, and 25%. Potential prognostic factors associated with overall survival (OS) were determined using the Cox regression model. OS curves were generated using Kaplan-Meier methods and survival differences compared using the log-rank test. Results One thousand three hundred seven consecutive cases of RCC were identified, of which 59 patients had sRCC (4.5%). As a continuous variable %Sarc was inversely associated with OS (P =.023). Predictors of survival on multivariable analysis included pathologic (p) T status, tumor size, clinical (c) M status and %Sarc at the 25% level. OS was most dependent on the presence of metastatic disease (4 months vs. 21.2 months; P =.001). In cM0 patients with locally advanced (≥ pT3) tumors, OS was significantly diminished in patients with > 25 %Sarc (P =.045). However, %Sarc did not influence OS in patients with cM1 disease. Conclusion Patients with sRCC have a poor overall outcome as evidenced by high rates of recurrence and death, indicating the need for more effective systemic therapies. In nonmetastatic patients, the incorporation of %Sarc in predictive nomograms might further improve risk stratification.
AB - Abstract Background The objective of this study was to determine if the percentage of sarcomatoid differentiation (%Sarc) in renal cell carcinoma (RCC) can be used for prognostic risk stratification, because sarcomatoid RCC (sRCC) is an aggressive variant of kidney cancer. Patients and Methods We performed a retrospective analysis of patients who underwent surgery for RCC at our institution between 1999 and 2012. Pathology slides for all sRCC cases were reexamined by a single pathologist and %Sarc was calculated. %Sarc was analyzed as a continuous variable and as a categorical variable at cut points of 5%, 10%, and 25%. Potential prognostic factors associated with overall survival (OS) were determined using the Cox regression model. OS curves were generated using Kaplan-Meier methods and survival differences compared using the log-rank test. Results One thousand three hundred seven consecutive cases of RCC were identified, of which 59 patients had sRCC (4.5%). As a continuous variable %Sarc was inversely associated with OS (P =.023). Predictors of survival on multivariable analysis included pathologic (p) T status, tumor size, clinical (c) M status and %Sarc at the 25% level. OS was most dependent on the presence of metastatic disease (4 months vs. 21.2 months; P =.001). In cM0 patients with locally advanced (≥ pT3) tumors, OS was significantly diminished in patients with > 25 %Sarc (P =.045). However, %Sarc did not influence OS in patients with cM1 disease. Conclusion Patients with sRCC have a poor overall outcome as evidenced by high rates of recurrence and death, indicating the need for more effective systemic therapies. In nonmetastatic patients, the incorporation of %Sarc in predictive nomograms might further improve risk stratification.
KW - Histology
KW - Kidney
KW - Overall survival
KW - Renal pathology
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=84929091692&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929091692&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2014.12.001
DO - 10.1016/j.clgc.2014.12.001
M3 - Article
C2 - 25544725
AN - SCOPUS:84929091692
SN - 1558-7673
VL - 13
SP - 225
EP - 230
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 3
M1 - 346
ER -